Capricor doses first subject in Phase III Duchenne muscular dystrophy trial
The double-blind, randomised, placebo-controlled trial will enrol nearly 70 subjects in the US.
A Program To Accelerate Sales
Cardiology trends: Stroke leads Twitter mentions in Q3 2021
Immunology trends: Asthma leads Twitter mentions in Q4 2020
Cardiovascular trends: Imaging leads Twitter mentions in Q4 2020
Roche’s Ocrevus set to top $7.6bn in sales by 2028 backed by new dosing approval
Astellas awarded funding for opioid use disorder trials of ASP8062
Gilead’s selonsertib fails in Phase III STELLAR-4 study for NASH
Pharmacovigilance and Post-Marketing Trials: Stavudine’s Last Fight – Part III
